BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-22.47M |
| Operating Margin | 0.00% |
| Return on Equity | -150.80% |
| Return on Assets | -79.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.36 |
| Price-to-Book | 1.36 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $8.53M |
| Float | $7.48M |
| % Insiders | 0.54% |
| % Institutions | 22.24% |
Volatility is currently contracting
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
BioVie Inc. (BIVI) Discusses Topline Phase 2 ADDRESS-LC Trial Data and the Potential of Bezisterim in Long Covid Transcript
Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET) Conference call scheduled for Tuesday, September 15, 2026, at 8:30 a.m. Eastern Time (ET)
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.
Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson's Disease
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that has completed the last on-treatment visit in its Phase 2 ADDRESS-LC clinical trial evaluating bezisterim in adults with Long COVID, with topline results targeted for release before the end of September 2026. The Carson City, Nevada-based clinical-stage company is developing therapies for neurological and neurodegenerative diseases.
CARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie Inc. (BIVI) Discusses Bezisterim Mechanism of Action and SUNRISE-PD Phase II Trial Design Transcript
For years, the hunt for a Parkinson's disease-modifying drug came down to one protein: alpha-synuclein. Clear it out, the thinking went, and you slow the disease.
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its drug candidate bezisterim met the prespecified endpoints of a Phase 2 trial in early-stage Parkinson's disease, with patients showing improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo. The SUNRISE-PD trial was a multicenter, randomized, double-blind, placebo-controlled study in patients with early-stage Parkinson's disease who had not previously been treated with carbidopa/levodopa.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BIVI and any ticker you trade — then tracks every position and per-strategy win rate.
